Global Computer Aided Detection Mammography Market Strategic Research Report

The global computer aided detection (CAD) mammography market occupies a critical position at the intersection of oncology diagnostics, medical imaging technology, and artificial intelligence-driven clinical decision support. Valued at approximately USD 1.02 billion in 2024, the market serves radiologists, breast imaging centers, hospital radiology departments, and outpatient diagnostic networks worldwide as they work to improve the sensitivity and specificity of breast cancer detection. Breast cancer remains the most frequently diagnosed cancer among women globally, with the World Health Organization estimating over 2.3 million new cases annually, creating sustained and growing demand for tools that reduce radiologist error rates, improve recall precision, and extend diagnostic coverage into under-resourced settings. CAD mammography systems — spanning traditional rule-based algorithms and newer deep learning architectures — have become standard workflow components across advanced screening programs in North America, Europe, and parts of Asia Pacific.

Growth in this market is being shaped by several converging forces. The rapid adoption of digital breast tomosynthesis (DBT), which generates substantially larger image datasets than conventional 2D mammography, has created near-mandatory demand for AI-assisted reading tools capable of processing three-dimensional slice data at clinical speed; this transition is directly accelerating CAD platform upgrades across major health systems. Simultaneously, government-mandated breast cancer screening programs in the European Union, the United States, and several Asian economies are expanding the volume of mammograms requiring interpretation, intensifying radiologist workload and reinforcing the economic case for automated second-read systems. A meaningful restraint on market expansion is the variability in reimbursement policy across payer systems: while the United States Centers for Medicare and Medicaid Services has historically provided separate reimbursement codes for CAD, inconsistent coverage in emerging markets and evolving payer attitudes toward standalone AI billing codes in Europe continue to create revenue uncertainty for solution providers.

This report delivers a comprehensive, data-anchored analysis of the global CAD mammography market from base year 2024 through the forecast horizon of 2032. It examines market segmentation by technology type and clinical application, provides granular regional and country-level forecasts, and profiles ten leading companies competing for share in this space. The report is essential reading for corporate strategy teams evaluating portfolio positioning, investment analysts modeling healthcare AI growth, M&A advisors assessing acquisition targets, and procurement managers benchmarking solution providers.